✦ LIBER ✦

Bevacizumab in lung cancer: hurdles in clinical development

✍ Scribed by Robert Pirker

Book ID: 117785429
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 79 KB
Volume: 11
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(10)70173-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeting angiogenesis in cancer: clinic

Targeting angiogenesis in cancer: clinical development of bevacizumab

✍ Kerr, David J 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 87 KB

Bevacizumab in Non-Small Cell Lung Cance

Bevacizumab in Non-Small Cell Lung Cancer

✍ Dr Francesco Di Costanzo, Francesca Mazzoni, Marinella Micol Mela, Lorenzo Anton 📂 Article 📅 2008 🏛 Springer International Publishing AG 🌐 English ⚖ 114 KB

Angiogenesis inhibitors in clinical deve

Angiogenesis inhibitors in clinical development for lung cancer

✍ Roy S Herbst; Manuel Hidalgo; A.Scott Pierson; Scott N Holden; Michael Bergen; S 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Bevacizumab AVAiLs in non-small cell lun

Bevacizumab AVAiLs in non-small cell lung cancer

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 179 KB

Tracheoesophageal Fistula Development an

Tracheoesophageal Fistula Development and Concurrent Chemoradiation and Bevacizumab in Non—Small-Cell Lung Cancer

✍ David R. Spigel; F. Anthony Greco; Cindy Farley; Christina Meng; Howard A. Burri 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 64 KB

Clinical development of irinotecan (CPT-

Clinical development of irinotecan (CPT-11) in lung cancers

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 180 KB